Plerixafor Patent Expiration
Plerixafor is Used for mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma and multiple myeloma for autologous transplantation. It was first introduced by Genzyme Corp
Plerixafor Patents
Given below is the list of patents protecting Plerixafor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mozobil | US6987102 | Methods to mobilize progenitor/stem cells |
Jul 22, 2023
(Expired) | Genzyme |
| Mozobil | US7897590 | Methods to mobilize progenitor/stem cells |
Jul 22, 2023
(Expired) | Genzyme |
| Mozobil | USRE42152 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec 10, 2018
(Expired) | Genzyme |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Plerixafor Generics
Several generic applications have been filed for Plerixafor. The first generic version for Plerixafor was by Dr Reddys Laboratories Ltd and was approved on Jul 24, 2023. And the latest generic version is by Gland Pharma Ltd and was approved on May 3, 2024.
Given below is the list of companies who have filed for Plerixafor generic.
1. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |
2. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |
3. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | May 3, 2024 |
4. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |
5. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |
6. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |
7. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Discontinued | SUBCUTANEOUS | N/A | Jul 26, 2023 |
8. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Plerixafor. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 24MG/1.2ML (20MG/ML) | solution | Prescription | SUBCUTANEOUS | AP | Jul 24, 2023 |